neu­ro­Care is pleased to announce the clos­ing of a seven-fig­ure invest­ment with Kyowa Phar­ma­ceu­ti­cals and bm|t – the company´s lead investor. This invest­ment will not only finance the company´s fur­ther expan­sion, includ­ing its Japan mar­ket entry, but also will safe­guard neuroCare’s growth and planned IPO beyond the cur­rent COVID19 cri­sis. neuroCare´s pur­pose is to per­son­al­ize men­tal health­care and per­for­mance. Through neuroCare´s plat­form, clin­i­cians are empow­ered to pro­vide per­son­al­ized and med­ica­tion-free ther­apy that addresses the under­ly­ing root causes of men­tal ill­ness by improv­ing patients´ abil­ity to self-reg­u­late. neuroCare’s approach gen­er­ates best-in-class clin­i­cal out­comes that are sus­tain­able over the long term and with­out neg­a­tive side effects. neu­ro­Care is ver­ti­cally inte­grated, oper­at­ing its own neu­ro­Clin­ics as well as pro­vid­ing its tech­nolo­gies, Stan­dard Oper­at­ing Pro­ce­dures and edu­ca­tion to its inhouse and third-party clin­ics through its neu­roSo­lu­tions divi­sion. Within the neu­roSo­lu­tions divi­sion, neu­ro­Cad­emy pro­vides Train­ing and Sci­ence & Super­vi­sion and neu­ro­Conn pro­vides neu­ro­mod­u­la­tion tech­nol­ogy. These key build­ing blocks enable neu­ro­Care to sup­port a grow­ing global net­work of clin­i­cians. bm|t is the pre­mier investor in the state of Thürin­gen and has a wealth of life sci­ence invest­ing expe­ri­ence, includ­ing invest­ments in mul­ti­ple pub­licly traded health­care com­pa­nies. Kevin Reeder, bm|t´s CEO, said of the company´s invest­ment in neu­ro­Care, “We are pleased to have re-invested in neu­ro­Care. We believe strongly in the company´s lead­er­ship and pur­pose and are eager to see the com­pany con­tinue on its path towards global lead­er­ship, espe­cially now, con­sid­er­ing the expected men­tal health strains caused by the cur­rent COVID19 cri­sis.” Tom Mechter­sheimer, neuroCare´s founder and Exec­u­tive Chair, con­cluded by stat­ing that “neu­ro­Care is dri­ving the future of men­tal health and cog­ni­tive per­for­mance with per­son­al­ized, objec­tive and mea­sur­able out­comes for every patient. We are very grate­ful for the con­tin­ued trust of bm|t who shares our con­vic­tion that men­tal health, espe­cially due to the effects of COVID-19, will be a major cri­sis to be addressed for a long time to come. Our pro­duc­tive and cost-effec­tive approach will help patients, clin­i­cians and pay­ors to deal with that huge challenge.”

Erfurt-based, beteili­gungs­man­age­ment Thürin­gen (bm|t) – a sub­sidiary of the Thürin­gen Devel­op­ment Bank, is the first address for invest­ments in Thürin­gen, Ger­many. bm‑t cur­rently man­ages eight invest­ment funds with a total vol­ume of 400M EUR. bm‑t invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all sec­tors and all phases of the cor­po­rate lifecycle.

 

Kyowa Phar­ma­ceu­ti­cal Indus­try Co., Ltd. (“Kyowa”)